Genetics

Mesoblast (Nasdaq:MESO) provided the market with an update on its operational highlights and consolidated financial results for the six months ended December 31, 2017 (the half-year of FY2018). As quoted in the press release: Revenues in the half-year of FY2018 were significantly increased to US$14.6 million, compared with US$0.9 million in the corresponding period in …

Mesoblast (Nasdaq:MESO) provided the market with an update on its operational highlights and consolidated financial results for the six months ended December 31, 2017 (the half-year of FY2018).

As quoted in the press release:

Revenues in the half-year of FY2018 were significantly increased to US$14.6 million, compared with US$0.9 million in the corresponding period in 2017, an increase of US$13.7 million. Net cash outflows from operating activities for the half-year were reduced by US$11.2 million (24%), compared with the half-year of FY2017. The Company recorded a profit after tax of US$6.7 million, compared with a loss after tax of US$39.8 million for the comparative period.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21205.16-69.41
TSXV900.87+10.01
DOW35028.65-339.82
S&P 5004532.76-44.35
NASD14340.26-166.64
ASX7332.50-76.30

COMMODITIES

Commodities
Gold1838.56+0.14
Silver24.20+0.12
Copper4.52+0.05
Palladium2071.50+91.00
Platinum1047.00+30.00
Oil86.79-0.17
Heating Oil2.62-0.02
Natural Gas4.01-0.03

DOWNLOAD FREE REPORTS

×